Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis.

ABSTRACT:

Objectives

Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how health effects and costs from funding an intervention are distributed among population subgroups. The objective was to evaluate how funding emicizumab for people with severe haemophilia A (PwSHA) impacts population health and health disparities in the USA.

Design

Population-level model of PwSHA from the perspective of the US healthcare system, using published sources and considering a lifetime time horizon.

Intervention

Emicizumab versus other haemophilia A prophylaxis treatments.

Primary outcome measures

Quality-a

SUBMITTER: Majda T 

PROVIDER: S-EPMC12421612 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature